STING1 and neoplasm: At present, the research progress of peptide tumor vaccines mainly revolves around the research of personalized peptide vaccines, tumor-associated antigens, and adjuvants (such as TLR agonists, STING agonists, cytokines) and delivery systems (such as nanoparticles, liposomes, and other novel delivery systems) to enhance immune response.